Drug Profile


Alternative Names: Anti-CD3 monoclonal antibody humanised - Protein Design Labs; HuM-291; Humanised anti-CD3 IgG2 antibody HuM291 gamma-2M3; Humanised monoclonal antibody M291; Monoclonal antibody anti-CD3 humanised; Nuvion; SMART anti-CD3 antibody; SMART anti-CD3 MAb; Visiluzumab

Latest Information Update: 10 Jul 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PDL BioPharma
  • Class Antipsoriatics; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Crohn's disease; Graft-versus-host disease; Psoriasis; Renal transplant rejection; Ulcerative colitis

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 19 Dec 2007 Discontinued - Phase-II for Ulcerative colitis in Canada (IV)
  • 19 Dec 2007 Discontinued - Phase-II for Ulcerative colitis in Europe (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top